10:31 AM EST - BioVaxys Technology Corp : Announces today that they have entered into a Research Agreement to develop mRNA-based Rabies, Leptospirosis, Feline Infectious Peritonitis (FIV and other mRNA-based vaccines for companion animal veterinary applications (dogs and cats). The collaboration utilizes BioVaxys' DPX™ Immune Educating Platform formulations with novel proprietary mRNA sequences coding for protective antigens designed and developed by Adiverna. BioVaxys Technology Corp
shares C.BIOV are trading unchanged at $0.10.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACC&qmodStoryID=7028781330694399
